Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
orphan-drug-designation
Press Release
Jun 27, 2023
ForCast Orthopedics Receives Orphan Drug Designation From FDA for the Treatment of Periprosthetic Joint Infection (PJI)
Read More
Press Release
Oct 3, 2022
Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose.
Read More
Press Release
Sep 6, 2022
Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to Interferon-Gamma-Neutralizing Antibody, EI-001 for the Treatment of Hemophagocytic Lymphohistiocytosis
Read More
Press Release
Aug 2, 2022
Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis
Read More
Press Release
Aug 28, 2020
TIKOMED Granted Orphan Medicinal Drug Designation for ILB® for the Treatment of Amyotrophic Lateral Sclerosis by the European Commission
Read More
Press Release
Jan 8, 2019
Philogen Receives Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma
Read More
Press Release
Jul 18, 2018
Philogen Receives Orphan Drug Designation for the Treatment of Melanoma
Read More
First
Prev
1
Next
Last